Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
ESMO Open|December 20, 2021
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global surveyT Cufer, M Kosty, P Osterlund, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancerR Paridaens, L Dirix, C Lohrisch, et al.European Journal of Cancer (Oxford, England : 1990)|November 7, 2003
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trialsG Atalay, L Biganzoli, F Renard, et al.Clinical Breast Cancer|April 24, 2002
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen controlR Paridaens, L Dirix, L Beex, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'G Atalay, L Dirix, L Biganzoli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialL Biganzoli, T Cufer, P Bruning, et al.The International Journal of Biological Markers|April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancerA Prechtl, N Harbeck, C Thomssen, et al.European Journal of Cancer (Oxford, England : 1990)|April 20, 2004
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancerF Efficace, L Biganzoli, M Piccart, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.Breast (Edinburgh, Scotland)|March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)F Cardoso, A Costa, L Norton, et al.Pageof 5